Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 - Clinical Trial Not Allowed)
ID: 352214Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352214

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-148.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 - Clinical Trial Not Allowed)" aimed at enhancing understanding of TDP-43 pathology and its relationship with cognitive decline in various neurodegenerative diseases. This initiative seeks innovative research proposals that explore mechanistic studies comparing at least two TDP-43 proteinopathies, with a focus on Alzheimer’s Disease Related Dementias (ADRD) and related syndromes, while excluding purely epidemiological or descriptive studies. The program is part of a broader effort to address national Alzheimer’s research priorities and will provide up to $4.5 million per year for six awards over five years, with applications accepted starting May 4, 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and the application deadline is set for October 4, 2024.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-148-Full-Announcement.html
    PAR-24-148.html
    The National Institutes of Health (NIH), specifically through the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Aging (NIA), has issued a Notice of Funding Opportunity (NOFO) focused on enhancing understanding of distinct and overlapping mechanisms in TDP-43 proteinopathies, including Alzheimer’s Disease Related Dementias (ADRD) and related syndromes like Limbic-predominant Age-related TDP-43 Encephalopathy (LATE) and Frontotemporal Degeneration (FTD). The funding opportunity, numbered PAR-24-148, aims to support innovative research that explores the causal relationships between TDP-43 pathology and cognitive decline. The program is open for applications beginning May 4, 2024, with a total funding of up to $4.5 million per year for six awards over five years. Eligible applicants include educational institutions, nonprofits, for-profits, and government entities. Projects must involve mechanistic studies comparing at least two TDP-43 proteinopathies, highlighting ADRD implications, and must avoid projects solely focused on epidemiology or descriptive studies. Applications will undergo rigorous scientific merit review, emphasizing the significance, methodology, and investigator qualifications. This funding initiative is part of broader efforts to address the national Alzheimer’s Disease research priorities outlined in the strategic plan set by the NIA and NINDS, committed to advancing Alzheimer’s research and increasing health equity in neurological outcomes across populations.
    Similar Opportunities
    Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanistic Investigations into Alzheimer’s Disease-Related Dementias (ADRD) Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)." This grant aims to support research that investigates the interactions of multiple co-pathologies associated with ADRD, focusing on their cellular and molecular mechanisms and their impact on cognitive and functional impairments. The initiative is part of a broader commitment to advance neuroscience research and address public health challenges related to dementia, with particular emphasis on studies that explore co-pathologies such as tau and alpha-synuclein. Interested applicants can apply for funding up to $500,000, with applications due by October 4, 2024. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html.
    Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the grant opportunity titled "Mechanistic Investigations into ADRD Associated Protein Structures in Biological Settings," aimed at enhancing the understanding of Alzheimer’s Disease Related Dementias (ADRD). This initiative focuses on utilizing structural biology methodologies to investigate the relationships between protein structures and clinical outcomes of ADRD, specifically seeking to generate structural information on proteins implicated in the disease within their native cellular environments. The NIH plans to allocate up to $3 million annually for up to four grants, with each grant not exceeding $500,000 per year for a maximum of five years, contingent upon funding availability. Interested applicants can submit their proposals starting September 4, 2024, with a submission deadline of October 5, 2024; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)" aimed at investigating the interactions between COVID-19 and Alzheimer’s Disease-Related Dementias (ADRD). This initiative seeks research proposals that utilize animal, cell culture, or human tissue models to explore the mechanisms by which COVID-19 affects CNS pathology and cognitive outcomes, particularly in the context of existing AD/ADRD conditions. The NIH plans to allocate up to $3.75 million to support up to five awards, with individual budgets capped at $500,000 in direct costs per year. Interested applicants must submit their proposals by October 4, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment," aimed at investigating the impact of environmental risk factors (ERFs) on Alzheimer's Disease-Related Dementia (ADRD). This initiative seeks to explore how exogenous ERFs, such as toxins and pathogens, influence ADRD mechanisms at innervated human surfaces, including the gut, lungs, and skin, while explicitly prohibiting clinical trials. The NIH plans to allocate up to $3.75 million annually for this initiative, with individual project budgets capped at $500,000 over a maximum duration of five years. Applications are due by October 6, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), has announced a funding opportunity titled "Deciphering the Impact of RNA Modifications on Brain Aging and AD/ADRD (R01 Clinical Trial Not Allowed)." This grant aims to support innovative research that elucidates the molecular mechanisms and functional implications of RNA modifications in relation to brain aging and Alzheimer's disease (AD) and related dementias (ADRD), including Lewy body dementia and frontotemporal dementia. The initiative is crucial for advancing understanding in this field, with the ultimate goal of identifying biomarkers and therapeutic targets that could lead to improved health outcomes for affected populations. Eligible applicants can request up to $500,000 in direct costs per year for projects lasting a maximum of five years, with a total funding allocation of $4 million for fiscal year 2025. Applications are due by November 1, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" aimed at developing a diverse and interdisciplinary workforce for translational research in this critical health area. The initiative invites eligible institutions to create training programs for predoctoral and postdoctoral researchers, focusing on enhancing skills in data science, disease biology, and drug discovery, while not permitting independent clinical trials. With an anticipated budget of approximately $2.7 million annually for 3-5 awards over fiscal years 2025-2027, applications are due by September 25, 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research on Alzheimer's Disease (AD) and its related dementias (ADRD) through the R21 Clinical Trial Optional grant. This grant aims to support innovative research methods and tools that advance understanding and treatment of AD/ADRD, particularly focusing on interdisciplinary studies that require preliminary data for broader application in the field. Given the increasing prevalence of AD and the associated public health concerns, this funding opportunity is crucial for fostering new approaches to address the complexities of the disease and its impact on diverse populations. Interested applicants can apply for up to $275,000 over a two-year period, with the application deadline set for November 12, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-094.html.
    Clinical Trial Readiness to Understand and Develop Solutions to Social, Ethical, Behavioral Implications and Barriers to Health Equity in ADRD (R01 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Clinical Trial Readiness to Understand and Develop Solutions to Social, Ethical, Behavioral Implications and Barriers to Health Equity in ADRD (R01 - Clinical Trial Not Allowed)." This initiative aims to support research that establishes clinical trial readiness for community-driven interventions addressing barriers to health equity in Alzheimer's Disease Related Dementias (ADRD) among populations experiencing health disparities. Successful applications must include a Community Engaged Research Inclusion (CERI) Plan and a Plan for Enhancing Diverse Perspectives (PEDP), focusing on social determinants of health and the unique challenges faced by diverse communities. NIH plans to allocate approximately $2.25 million to fund three awards, with each project eligible for a maximum budget of $500,000 per year for up to four years. Applications are due by October 4, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline" grant, aimed at developing interventions to prevent or treat cognitive and behavioral changes associated with Alzheimer's disease (AD) and related dementias (ADRD). The funding opportunity seeks to support both pharmacological and non-pharmacological clinical trials, with a focus on enhancing trial design and methodologies to address the growing public health crisis posed by these conditions, which currently affect over 6 million Americans. The total funding allocation for fiscal year 2025 is approximately $20 million, with applications due by October 17, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)" grant, aimed at advancing research on Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity seeks to support high-priority research initiatives that address the growing public health crisis posed by these conditions, particularly among older adults. Eligible applicants include a diverse range of entities such as educational institutions, non-profits, and tribal governments, with funding decisions based on the scientific merit of proposals and the qualifications of the investigators. Applications are due by November 12, 2024, and interested parties can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.